vincislato
Forumer attivo
una spazzolatina da 5000 azioni 
El.En (ELN) El.En.: la bella addormentata con oltre 60 milioni di "dote"...
- Creatore Discussione Spotti
- Data di Inizio
vincislato
Forumer attivo
elenina ha di nuovo il febbrone.... che nessuno si permetta di curarla...
P.S. e il lock out di CYNO per avere mani libere si avvicina... ci starebbe un tic tac... solo che visto l'effetto su altri titoli, mi sa che porta sfiga...
P.S. e il lock out di CYNO per avere mani libere si avvicina... ci starebbe un tic tac... solo che visto l'effetto su altri titoli, mi sa che porta sfiga...
vincislato
Forumer attivo
febbrone a 40... NON CHIAMATE IL DOTTOREEEEEE
franci63
Forumer storico
elenina ha di nuovo il febbrone.... che nessuno si permetta di curarla...
P.S. e il lock out di CYNO per avere mani libere si avvicina... ci starebbe un tic tac... solo che visto l'effetto su altri titoli, mi sa che porta sfiga...
quando scade?
vincislato
Forumer attivo
vi sono diverse ipotesi/ricordi ma convergono tutte entro la fine dell'anno - inizio 2016. bisognerebbe controllare quando El.en ha smesso di avere il controllo di CYNO.
franci63
Forumer storico
vincislato
Forumer attivo
febbrone persistente
Spotti
.
febbrone persistente
Sembra che gli antibiotici abbiano poco effetto anche perché Cynosure continua a "tirare la volata" (ormai siamo oltre i 42$)!
vincislato
Forumer attivo
febbre febbre febbbbbbroooooneeee
vincislato
Forumer attivo
cynosure risultati:
- dati buoni
- investimenti dedicati a MonaLisa (roba nostra!!!...)
- Nord America che va benone (e quindi positivo per El.En)
- debolezza su mercato europeo e cinese (e qui se la debolezza di Cyno fosse dovuta più a cambio sfavorevole che all'andamento economico - sarebbero botti per El.En)..
- tutto fa pensare a trimestrale di El.En molto solida.
Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year
WESTFORD, Mass., May 5, 2015 /PRNewswire/ -- Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended March 31, 2015.
First-Quarter Highlights:
North America product revenue growth of 45 percent
Non-GAAP earnings of $0.15 per share; GAAP earnings break-even
Cash and investments of $126.6 million at March 31, 2015
"Cynosure delivered 21 percent year-over-year top-line growth in the first quarter, reflecting higher laser revenue in North America, which was up 45 percent from the same period last year," said Michael Davin, Cynosure's Chairman and Chief Executive Officer. "While we believe our international performance was temporarily affected by external factors including economic weakness in Europe and unfavorable currency movements, these were more than offset by our strong domestic results. We also continue to advance the development of new products that expand and diversify our business.
"We are expanding our leadership in the non-invasive aesthetic market with the development of new technology, including our new non-invasive body contouring product, which is designed to eliminate fat by disrupting adipose tissue," Davin said. "Our 510(k) for this device was submitted to the U.S. Food and Drug Administration in January, and pending regulatory clearance we are targeting launch later in the second half of 2015. Our 510(k) submission is supported by clinical data in multicenter studies from approximately 100 subjects. Researchers saw a statistically significant reduction in adipose layer thickness six and 12 weeks post-treatment. In a separate pilot clinical study, our hyperthermic lipolysis technique compared favorably with cryolipolysis in average fat reduction at three and six months post-treatment.
"We've also made good progress in building the marketing foundation for MonaLisa Touch™, our first product specifically for women's health and wellness," Davin said. "After securing exclusive North American distribution rights to the product, we recently completed hiring 13 specialty sales reps to market MonaLisa Touch to physicians. Through a physician marketing strategy that includes trade shows, workshops and webinars, we are driving awareness about the availability of the MonaLisa Touch treatment and generating interest in the product from a number of key opinion leaders. The initial response in the marketplace has been positive."
First-Quarter 2015 Financial Results
Revenue was $74.9 million, an increase of 21 percent from the prior-year period. Product revenue in North America grew 45 percent to $31.3 million. International product revenue was $25.2 million, down 10 percent year-over-year due in part to a $1.7 million decrease based on unfavorable foreign currency exchange rates. Revenue from parts, service, disposables and royalty revenues increased 50 percent to $18.4 million, which included the final $3 million payment due under a previously disclosed settlement agreement with Tria Beauty.
Operating income was $2.1 million, up 53 percent year-over-year. On a non-GAAP basis, excluding acquisition costs and amortization of intangibles, income from operations was $5.1 million, up 4 percent from the first quarter of 2014.
On a GAAP basis, the Company reported break-even net income for the first quarter of 2015, or $0.00 per share, compared with net income of $0.7 million, or $0.03 per diluted share, for the prior-year period. GAAP earnings included a $1.7 million unrealized loss on foreign currency and a $0.1 million unrealized gain on foreign currency for the 2015 and 2014 periods, respectively.
Excluding acquisition costs, amortization of intangibles and unrealized foreign exchange impact, non-GAAP net income for the first quarter of 2015 was $3.3 million, or $0.15 per diluted share, compared with $3.2 million, or $0.14 per diluted share, for the first quarter of 2014, primarily reflecting increased investments in sales and marketing associated with new products and the hiring of a specialty sales force for MonaLisa Touch in the first quarter of this year.
Cash and investments at March 31, 2015 was $126.6 million, compared with $133.4 million at year-end 2014.
Business Outlook
"Our commitment to invest in innovation, develop unique new products and capitalize on new market opportunities continues to produce positive results for Cynosure," Davin said. "With the rollout of our new 532 nm laser delivery system for PicoSure® announced in February, the momentum of MonaLisa Touch and, pending regulatory clearance, the anticipated launch of our new non-invasive technology for fat removal, we look forward to a strong and successful year
- dati buoni
- investimenti dedicati a MonaLisa (roba nostra!!!...
)- Nord America che va benone (e quindi positivo per El.En)
- debolezza su mercato europeo e cinese (e qui se la debolezza di Cyno fosse dovuta più a cambio sfavorevole che all'andamento economico - sarebbero botti per El.En)..
- tutto fa pensare a trimestrale di El.En molto solida.
Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year
WESTFORD, Mass., May 5, 2015 /PRNewswire/ -- Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended March 31, 2015.
First-Quarter Highlights:
North America product revenue growth of 45 percent
Non-GAAP earnings of $0.15 per share; GAAP earnings break-even
Cash and investments of $126.6 million at March 31, 2015
"Cynosure delivered 21 percent year-over-year top-line growth in the first quarter, reflecting higher laser revenue in North America, which was up 45 percent from the same period last year," said Michael Davin, Cynosure's Chairman and Chief Executive Officer. "While we believe our international performance was temporarily affected by external factors including economic weakness in Europe and unfavorable currency movements, these were more than offset by our strong domestic results. We also continue to advance the development of new products that expand and diversify our business.
"We are expanding our leadership in the non-invasive aesthetic market with the development of new technology, including our new non-invasive body contouring product, which is designed to eliminate fat by disrupting adipose tissue," Davin said. "Our 510(k) for this device was submitted to the U.S. Food and Drug Administration in January, and pending regulatory clearance we are targeting launch later in the second half of 2015. Our 510(k) submission is supported by clinical data in multicenter studies from approximately 100 subjects. Researchers saw a statistically significant reduction in adipose layer thickness six and 12 weeks post-treatment. In a separate pilot clinical study, our hyperthermic lipolysis technique compared favorably with cryolipolysis in average fat reduction at three and six months post-treatment.
"We've also made good progress in building the marketing foundation for MonaLisa Touch™, our first product specifically for women's health and wellness," Davin said. "After securing exclusive North American distribution rights to the product, we recently completed hiring 13 specialty sales reps to market MonaLisa Touch to physicians. Through a physician marketing strategy that includes trade shows, workshops and webinars, we are driving awareness about the availability of the MonaLisa Touch treatment and generating interest in the product from a number of key opinion leaders. The initial response in the marketplace has been positive."
First-Quarter 2015 Financial Results
Revenue was $74.9 million, an increase of 21 percent from the prior-year period. Product revenue in North America grew 45 percent to $31.3 million. International product revenue was $25.2 million, down 10 percent year-over-year due in part to a $1.7 million decrease based on unfavorable foreign currency exchange rates. Revenue from parts, service, disposables and royalty revenues increased 50 percent to $18.4 million, which included the final $3 million payment due under a previously disclosed settlement agreement with Tria Beauty.
Operating income was $2.1 million, up 53 percent year-over-year. On a non-GAAP basis, excluding acquisition costs and amortization of intangibles, income from operations was $5.1 million, up 4 percent from the first quarter of 2014.
On a GAAP basis, the Company reported break-even net income for the first quarter of 2015, or $0.00 per share, compared with net income of $0.7 million, or $0.03 per diluted share, for the prior-year period. GAAP earnings included a $1.7 million unrealized loss on foreign currency and a $0.1 million unrealized gain on foreign currency for the 2015 and 2014 periods, respectively.
Excluding acquisition costs, amortization of intangibles and unrealized foreign exchange impact, non-GAAP net income for the first quarter of 2015 was $3.3 million, or $0.15 per diluted share, compared with $3.2 million, or $0.14 per diluted share, for the first quarter of 2014, primarily reflecting increased investments in sales and marketing associated with new products and the hiring of a specialty sales force for MonaLisa Touch in the first quarter of this year.
Cash and investments at March 31, 2015 was $126.6 million, compared with $133.4 million at year-end 2014.
Business Outlook
"Our commitment to invest in innovation, develop unique new products and capitalize on new market opportunities continues to produce positive results for Cynosure," Davin said. "With the rollout of our new 532 nm laser delivery system for PicoSure® announced in February, the momentum of MonaLisa Touch and, pending regulatory clearance, the anticipated launch of our new non-invasive technology for fat removal, we look forward to a strong and successful year
Similar threads
